Globus Medical Inc. Class A Common Stock vs Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares USD1.00 par value) — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares USD1.00 par value) trades at $58.55 (market cap $11.58B). The key difference: Globus Medical Inc. Class A Common Stock and Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares USD1.00 par value) are close in size by market cap, and Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares USD1.00 par value) pays a 3.73% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares USD1.00 par value) for 0 Days on average.
| GMED | TX | |
|---|---|---|
Market Cap | $10.25B | $11.58B |
Volume | 1,108,124 | 456,367 |
Sector | Health | Basic Materials |
52-Week High | $96.82 | $58.99 |
52-Week Low | $58.33 | $35.26 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $9.76B | $11.90B |
Dividend Yield | — | 3.73% |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Ternium (TX) trades at $58.99, up 1.81% with strong Q2 2026 earnings beating estimates by 43%. The stock shows solid fundamentals with attractive valuation metrics including P/E of 16.39 and P/S of 0.72. Recent analyst upgrades to Strong Buy highlight improving sentiment as Mexico's steel recovery drives operational momentum and the $4B Pesqueria project promises future capacity growth.
The stock offers value with 7% dividend yield projections and 14.5% upside to $65.52 fair value. Key risks include steel price volatility and trade uncertainty, but declining CapEx should boost free cash flow above 15% yield. Analyst consensus at $57.17 with 50% Buy ratings supports cautious optimism for continued recovery.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →Ternium S.A. is a Luxembourg-headquartered steel producer operating an integrated production system, from mining through finished flat and long steel products. It runs 18 production plants and two mining operations across Argentina, Brazil, Colombia, Guatemala, Mexico, and US, serving the automotive, construction, appliance, and energy industries.
Read more on TX →